We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

34 hedge funds and large institutions have $4.32M invested in Regulus Therapeutics in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 6

21% more funds holding

Funds holding: 28 → 34 (+6)

9% more capital invested

Capital invested by funds: $3.97M → $4.32M (+$344K)

1.8% less ownership

Funds ownership: 4.1% → 2.3% (-1.8%)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
34
Holders Change
+6
Holders Change %
+21.43%
% of All Funds
0.7%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
12
Increased
4
Reduced
5
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$35.1K
2
TRCT
Tower Research Capital (TRC)
New York
+$28.9K
3
SG Americas Securities
SG Americas Securities
New York
+$22.9K
4
Jane Street
Jane Street
New York
+$13.2K
5
GC
Grimes & Company
Massachusetts
+$12.8K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$870K
2
Renaissance Technologies
Renaissance Technologies
New York
-$145K
3
CH
CVI Holdings
Delaware
-$129K
4
BI
BVF Inc
California
-$93.5K
5
Rockefeller Capital Management
Rockefeller Capital Management
New York
-$39K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$1.4M – – –
SCM
2
Sarissa Capital Management
Connecticut
$1.26M – – –
BI
3
BVF Inc
California
$988K -$93.5K -14,292 -9%
Renaissance Technologies
4
Renaissance Technologies
New York
$201K -$145K -22,122 -43%
VF
5
Virtu Financial
New York
$57K +$55.2K +8,435 New
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$44K -$3.65K -558 -8%
BlackRock
7
BlackRock
New York
$44K +$10.5K +1,599 +33%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$43K – – –
Millennium Management
9
Millennium Management
New York
$37K +$35.1K +5,357 New
TRCT
10
Tower Research Capital (TRC)
New York
$30K +$28.9K +4,419 New
SG Americas Securities
11
SG Americas Securities
New York
$24K +$22.9K +3,500 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$22K – – –
Northern Trust
13
Northern Trust
Illinois
$16K +$5.5K +840 +54%
WS
14
Wedbush Securities
California
$14K -$105 -16 -0.8%
MIG
15
McGuire Investment Group
Rhode Island
$14K +$655 +100 +5%
Jane Street
16
Jane Street
New York
$14K +$13.2K +2,017 New
GC
17
Grimes & Company
Massachusetts
$13K +$12.8K +1,950 New
Wells Fargo
18
Wells Fargo
California
$12K -$2.98K -456 -21%
Acadian Asset Management
19
Acadian Asset Management
Massachusetts
$12K +$11.6K +1,768 New
Two Sigma Investments
20
Two Sigma Investments
New York
$11K +$10.7K +1,633 New
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$10K – – –
Simplex Trading
22
Simplex Trading
Illinois
$10K – – –
William Blair & Company
23
William Blair & Company
Illinois
$8K – – –
ARTA
24
A.R.T. Advisors
New York
$8K +$7.72K +1,180 New
TSS
25
Two Sigma Securities
New York
$8K +$7.79K +1,191 New
1
2

RGLS Hedge Fund Activity: Q2 2020 in Review

34 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2020, worth a combined $4.32M — up 8.7% from $3.97M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new RGLS positions and 6 closed out — a net gain of 6 holders — while 4 added to existing stakes and 5 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $35.1K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $870K sold.

  • 34 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2020, up from 28 in Q1 2020.
  • Funds reported $4.32M of Regulus Therapeutics stock for Q2 2020, up 8.7% quarter-over-quarter.
  • 12 funds opened new Regulus Therapeutics positions in Q2 2020 and 6 closed out, a net change of +6 holders.
  • The largest Regulus Therapeutics buyer in Q2 2020 was Millennium Management, an estimated $35.1K added.
  • The largest Regulus Therapeutics seller in Q2 2020 was EcoR1 Capital, an estimated $870K sold.

Based on aggregated 13F filings for Q2 2020.